Abraham W M, Sielczak M W, Ahmed A, Cortes A, Lauredo I T, Kim J, Pepinsky B, Benjamin C D, Leone D R, Lobb R R
Department of Medicine, University of Miami, Mount Sinai Medical Center, Florida 33140.
J Clin Invest. 1994 Feb;93(2):776-87. doi: 10.1172/JCI117032.
Eosinophils and T lymphocytes are thought to be involved in allergic airway inflammation. Both cells express the alpha 4 beta 1-integrin, very late antigen-4 (VLA-4, CD49d/CD29); alpha 4-integrins can promote cellular adhesion and activation. Therefore, we examined the in vivo effects of a blocking anti-alpha 4 monoclonal antibody, HP 1/2, on antigen-induced early and late bronchial responses, airway hyperresponsiveness, inflammatory cell influx, and peripheral leukocyte counts in allergic sheep. Sheep blood lymphocytes, monocytes, and eosinophils expressed alpha 4 and bound HP 1/2. In control sheep, Ascaris antigen challenge produced early and late increases in specific lung resistance of 380 +/- 42% and 175 +/- 16% over baseline immediately and 7 h after challenge, respectively, as well as airway hyperresponsiveness continuing for 14 d after antigen challenge. Treatment with HP 1/2 (1 mg/kg, i.v.) 30 min before antigen challenge did not affect the early increase in specific lung resistance but inhibited the late-phase increase at 5-8 h by 75% (P < 0.05) and inhibited the post-antigen-induced airway hyperresponsiveness at 1, 2, 7, and 14 d (P < 0.05, for each time). Intravenous HP 1/2 given 2 h after antigen challenge likewise blocked late-phase airway changes and postchallenge airway hyperresponsiveness. Airway administration of HP 1/2 (16-mg dose) was also effective in blocking these antigen-induced changes. Response to HP 1/2 was specific since an isotypic monoclonal antibody, 1E6, was ineffective by intravenous and aerosol administration. Inhibition of leukocyte recruitment did not totally account for the activity of anti-alpha 4 antibody since HP 1/2 neither diminished the eosinopenia or lymphopenia that followed antigen challenge nor consistently altered the composition of leukocytes recovered by bronchoalveolar lavage. Because airway administration of HP 1/2 was also active, HP 1/2 may have inhibited cell activation. Reduction of platelet-activating factor-induced eosinophil peroxidase release from HP 1/2-treated eosinophils supports such a mechanism. These findings indicate a role for alpha 4-integrins in processes that lead to airway late phase responses and persisting airway hyperresponsiveness after antigen challenge.
嗜酸性粒细胞和T淋巴细胞被认为参与了过敏性气道炎症。这两种细胞均表达α4β1整合素,即极迟抗原-4(VLA-4,CD49d/CD29);α4整合素可促进细胞黏附和活化。因此,我们研究了一种阻断性抗α4单克隆抗体HP 1/2对变应性绵羊抗原诱导的早期和晚期支气管反应、气道高反应性、炎症细胞浸润及外周血白细胞计数的体内作用。绵羊血淋巴细胞、单核细胞和嗜酸性粒细胞表达α4并能结合HP 1/2。在对照绵羊中,蛔虫抗原激发后,特异性肺阻力立即和激发后7小时分别比基线水平早期升高380±42%和晚期升高175±16%,抗原激发后气道高反应性持续14天。抗原激发前30分钟静脉注射HP 1/2(1毫克/千克)不影响特异性肺阻力的早期升高,但在5至8小时抑制晚期升高75%(P<0.05),并在1、2、7和14天抑制抗原激发后诱导的气道高反应性(每次P<0.05)。抗原激发后2小时静脉注射HP 1/2同样可阻断晚期气道变化和激发后气道高反应性。气道给予HP 1/2(16毫克剂量)也能有效阻断这些抗原诱导的变化。对HP 1/2的反应具有特异性,因为同型单克隆抗体1E6经静脉注射和气溶胶给药均无效。白细胞募集抑制并不能完全解释抗α4抗体的活性,因为HP 1/2既未减轻抗原激发后出现的嗜酸性粒细胞减少或淋巴细胞减少,也未持续改变支气管肺泡灌洗回收的白细胞组成。由于气道给予HP 1/2也有活性,HP 1/2可能抑制了细胞活化。HP 1/2处理的嗜酸性粒细胞中血小板活化因子诱导的嗜酸性粒细胞过氧化物酶释放减少支持了这一机制。这些发现表明α4整合素在导致抗原激发后气道晚期反应和持续气道高反应性的过程中起作用。